Table 1 Risk of type 2 diabetes, all-cause mortality, major osteoporotic fracture and dementia in participants initiating fenofibrate compared to those using simvastatin

From: Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence

 

Fenofibrate

Simvastatin

Incident type 2 diabetes

  

Participantsa, n

1,602

6,384

Events, n

62

335

Mean follow-up (years)

0.93

0.94

Rate of event, per 1,000 person-years

41.4

55.9

RD (95% CI), per 1,000 person-years

−14.5 (−26.4 to −2.6)

0.0 (reference)

HR (95% CI)

0.59 (0.46–0.76)

1.00 (reference)

All-cause mortality

  

Participantsb, n

7,236

28,086

Events, n

73

354

Mean follow-up (years)

0.97

0.97

Rate of event, per 1,000 person-years

10.4

13.0

RD (95% CI), per 1,000 person-years

−2.6 (−5.2 to 0.0)

0.0 (reference)

HR (95% CI)

0.78 (0.60–1.00)

1.00 (reference)

Incident major osteoporotic fracture

  

Participantsc, n

6,749

25,923

Events, n

19

120

Mean follow-up (years)

0.97

0.97

Rate of event, per 1,000 person-years

2.9

4.8

RD (95% CI), per 1,000 person-years

−1.9 (−3.4 to −0.3)

0.0 (reference)

HR (95% CI)

0.51 (0.33–0.81)

1.00 (reference)

Incident dementia

  

Participantsd, n

7,201

27,924

Events, n

12

102

Mean follow-up (years)

0.97

0.97

Rate of event, per 1,000 person-years

1.7

3.7

RD (95% CI), per 1,000 person-years

−2.0 (−3.3 to −0.8)

0.0 (reference)

HR (95% CI)

0.51 (0.29–0.89)

1.00 (reference)

  1. RD, rate difference; HR, hazard ratio; 95% CI, 95% confidence interval.
  2. aIncluding participants with pre-diabetes.
  3. bIncluding participants with pre-diabetes and type 2 diabetes.
  4. cIncluding participants with pre-diabetes and type 2 diabetes and excluding those with a history of major osteoporotic fracture.
  5. dIncluding participants with pre-diabetes and type 2 diabetes and excluding those with a history of dementia.
Back to article page